Comparing the role of anti-Müllerian hormone as a marker of FSH action in male and female fertility

References

• Josso N. Professor Alfred Jost: the builder of modern sex differentiation. Sex Dev. 2008;2(2):55–63.
   PubMed Web of Science ®Google Scholar
• Picard JY, Cate RL, Racine C, et al. The persistent mullerian duct syndrome: an update based upon a personal experience of 157 cases. Sex Dev. 2017;11:109–125.
   PubMed Web of Science ®Google Scholar
• Cate RL, Mattaliano RJ, Hession C, et al. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell. 1986;45(5):685–698.
   PubMed Web of Science ®Google Scholar
• Josso N, Lamarre I, Picard JY, et al. Anti-Müllerian hormone in early human development. Early Hum Dev. 1993;33(2):91–99.
   PubMed Web of Science ®Google Scholar
• Edelsztein NY, Racine C, Di Clemente N, et al. Androgens downregulate anti-Mullerian hormone promoter activity in the Sertoli cell through the androgen receptor and intact SF1 sites. Biol Reprod. 2018;99:1303–1312.
   PubMed Web of Science ®Google Scholar
• Lee MM, Donahoe PK, Silverman BL, et al. Measurements of serum Müllerian inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med. 1997;336(21):1480–1486.
   PubMed Web of Science ®Google Scholar
• Lee MM, Misra M, Donahoe PK, et al. MIS/AMH in the assessment of cryptorchidism and intersex conditions. Mol Cell Endocrinol. 2003;211:91–98.
   PubMed Web of Science ®Google Scholar
• Ahmed SF, Keir L, McNeilly J, et al. The concordance between serum anti-Mullerian hormone and testosterone concentrations depends on duration of hCG stimulation in boys undergoing investigation of gonadal function. Clin Endocrinol (Oxf). 2010;72(6):814–819.
   PubMed Web of Science ®Google Scholar
• Grinspon RP, Rey RA. Anti-mullerian hormone and Sertoli cell function in paediatric male hypogonadism. Horm Res Paediatr. 2010;73(2):81–92.
   PubMed Web of Science ®Google Scholar
• Grinspon RP, Bedecarrás P, Ballerini MG, et al. Early onset of primary hypogonadism revealed by serum anti-Müllerian hormone determination during infancy and childhood in trisomy 21. Int J Androl. 2011;34(5pt2):e487–e498.
   PubMedGoogle Scholar
• Grinspon RP, Andreone L, Bedecarrás P, et al. Male Central Precocious Puberty: Serum Profile of Anti-Mullerian Hormone and Inhibin B before, during, and after Treatment with GnRH Analogue. Int J Endocrinol. 2013;823064:2013.
   Google Scholar
• Josso N, Rey RA, Picard JY. Anti-müllerian hormone: a valuable addition to the toolbox of the pediatric endocrinologist. Int J Endocrinol. 2013;674105:2013.
   Google Scholar
• Grinspon RP, Habib C, Bedecarrás P, et al. Compensatory function of the remaining testis is dissociated in boys and adolescents with monorchidism. Eur J Endocrinol. 2016;174(3):399–407.
   PubMed Web of Science ®Google Scholar
• Lindhardt Johansen M, Hagen CP, Johannsen TH, et al. Anti-mullerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development. Int J Endocrinol. 2013;198698:2013.
   Google Scholar
• Grinspon RP, Gottlieb S, Bedecarras P, et al. Anti-Müllerian hormone and testicular function in prepubertal boys with cryptorchidism. Front Endocrinol (Lausanne). 2018;9:182.
   PubMed Web of Science ®Google Scholar
• Bézard J, Vigier B, Tran D, et al. Immunocytochemical study of anti-Müllerian hormone in sheep ovarian follicles during fetal and post-natal development. J Reprod Fertil. 1987;80(2):509–516.
   PubMedGoogle Scholar
• Ueno S, Takahashi M, Manganaro TF, et al. Cellular localization of mullerian inhibiting substance in the developing rat ovary. Endocrinology. 1989;124(2):1000–1006.
   PubMed Web of Science ®Google Scholar
• Rajpert-De Meyts E, Jørgensen N, Græm N, et al. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab. 1999;84(10):3836–3844.
   PubMed Web of Science ®Google Scholar
• Rey R, Sabourin JC, Venara M, et al. Anti-Mullerian hormone is a specific marker of sertoli- and granulosa-cell origin in gonadal tumors. Hum Pathol. 2000;31(10):1202–1208.
   PubMed Web of Science ®Google Scholar
• Dutertre M, Gouédard L, Xavier F, et al. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Mullerian hormone in transgenic mice. Endocrinology. 2001;142(9):4040–4046.
   PubMed Web of Science ®Google Scholar
• Kuiri-Hänninen T, Kallio S, Seuri R, et al. Postnatal developmental changes in the pituitary-ovarian axis in preterm and term infant girls. J Clin Endocrinol Metab. 2011;96(11):3432–3439.
   PubMed Web of Science ®Google Scholar
• Vigier B, Picard JY, Tran D, et al. Production of anti-Müllerian hormone: another homology between Sertoli and granulosa cells. Endocrinology. 1984;114(4):1315–1320.
   PubMed Web of Science ®Google Scholar
• Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod. 2013;19(8):519–527.
   PubMed Web of Science ®Google Scholar
• Baarends WM, Uilenbroek JT, Kramer P, et al. Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology. 1995;136(11):4951–4962.
   PubMed Web of Science ®Google Scholar
• Ueno S, Kuroda T, MacLaughlin DT, et al. Mullerian inhibiting substance in the adult rat ovary during various stages of the estrous cycle. Endocrinology. 1989;125(2):1060–1066.
   PubMed Web of Science ®Google Scholar
• Weenen C, Laven JSE, vonBergh ARM, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol.Hum.Reprod. 2004;10(2):77–83.
   PubMed Web of Science ®Google Scholar
• Rey RA, Lhommé C, Marcillac I, et al. Antimüllerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum alpha-inhibin and estradiol. Am J Obstet Gynecol. 1996;174(3):958–965.
   PubMed Web of Science ®Google Scholar
• Long WQ, Ranchin V, Pautier P, et al. Detection of minimal levels of serum anti-Müllerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab. 2000;85(2):540–544.
   PubMed Web of Science ®Google Scholar
• Hagen CP, Aksglæde L, Sorensen K, et al. Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab. 2010;95(11):5003–5010.
   PubMed Web of Science ®Google Scholar
• Broer SL, Eijkemans MJ, Scheffer GJ, et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab. 2011;96(8):2532–2539.
   PubMed Web of Science ®Google Scholar
• Lie Fong S, Visser JA, Welt CK, et al. Serum anti-mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab. 2012;97(12):4650–4655.
   PubMed Web of Science ®Google Scholar
• Elchuri SV, Patterson BC, Brown M, et al. Low anti-mullerian hormone in pediatric cancer survivors in the early years after gonadotoxic therapy. J Pediatr Adolesc Gynecol. 2016;29(4):393–399.
   PubMed Web of Science ®Google Scholar
• Wedrychowicz A, Wojtys J, Starzyk J. Anti-Muellerian hormone (AMH) as only possible marker in the assessment of ovarian function and reserve after hematopoietic stem cell transplantation (HSCT) in prepubertal girls, young females with composed hypogonadism and females receiving hormonal replacement therapy. Bone Marrow Transplant. 2017;52(2):313–316.
   PubMed Web of Science ®Google Scholar
• Broer SL, Broekmans FJ, Laven JS, et al. Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20(5):688–701.
   PubMed Web of Science ®Google Scholar
• Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-Mullerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update. 2015;21(6):698–710.
   PubMed Web of Science ®Google Scholar
• Kumar TR. Fshb knockout mouse model, two decades later and into the future. Endocrinology. 2018;159(5):1941–1949.
   PubMed Web of Science ®Google Scholar
• Siegel ET, Kim HG, Nishimoto HK, et al. The molecular basis of impaired follicle-stimulating hormone action: evidence from human mutations and mouse models. Reprod Sci. 2013;20(3):211–233.
   PubMed Web of Science ®Google Scholar
• Jonas KC, Oduwole OO, Peltoketo H, et al. Mouse models of altered gonadotrophin action: insight into male reproductive disorders. Reproduction. 2014;148(4):R63–70.
   PubMed Web of Science ®Google Scholar
• Grinspon RP, Urrutia M, Rey RA. Male central hypogonadism in paediatrics – the relevance of follicle-stimulating hormone and sertoli cell markers. Eur Endocrinol. 2018;14:67–71.
   PubMedGoogle Scholar
• Arango NA, Lovell-Badge R, Behringer RR. Targeted mutagenesis of the endogenous mouse Mis gene promoter: in vivo definition of genetic pathways of vertebrate sexual development. Cell. 1999;99(4):409–419.
   PubMed Web of Science ®Google Scholar
• Lasala C, Carré-Eusèbe D, Picard JY, et al. Subcellular and molecular mechanisms regulating anti-Müllerian hormone gene expression in mammalian and nonmammalian species. DNA Cell Biol. 2004;23(9):572–585.
   PubMed Web of Science ®Google Scholar
• Salmon NA, Handyside AH, Joyce IM. Expression of Sox8, Sf1, Gata4, Wt1, Dax1, and Fog2 in the mouse ovarian follicle: implications for the regulation of Amh expression. Mol Reprod Dev. 2005;70(3):271–277.
   PubMed Web of Science ®Google Scholar
• Pelusi C, Ikeda Y, Zubair M, et al. Impaired follicle development and infertility in female mice lacking steroidogenic factor 1 in ovarian granulosa cells. Biol Reprod. 2008;79(6):1074–1083.
   PubMed Web of Science ®Google Scholar
• França LR, Hess RA, Dufour JM, et al. The Sertoli cell: one hundred fifty years of beauty and plasticity. Andrology. 2016;4(2):189–212.
   PubMed Web of Science ®Google Scholar
• Chemes HE. Infancy is not a quiescent period of testicular development. Int.J.Androl. 2001;24(1):2–7.
   PubMedGoogle Scholar
• McLean DJ, Friel PJ, Pouchnik D, et al. Oligonucleotide microarray analysis of gene expression in follicle-stimulating hormone-treated rat Sertoli cells. Mol Endocrinol. 2002;16(12):2780–2792.
   PubMedGoogle Scholar
• Orth JM, Gunsalus GL, Lamperti AA. Evidence from Sertoli cell-depleted rats indicates that spermatid number in adults depends on numbers of Sertoli cells produced during perinatal development. Endocrinology. 1988;122(3):787–794.
   PubMed Web of Science ®Google Scholar
• Kumar TR, Wang Y, Lu N, et al. Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nat Genet. 1997;15(2):201–204.
   PubMed Web of Science ®Google Scholar
• Dierich A, Ram Sairam M, Monaco L, et al. Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc Natl Acad Sci USA. 1998;95(23):13612–13617.
   PubMed Web of Science ®Google Scholar
• Braslavsky D, Grinspon RP, Ballerini MG, et al. Hypogonadotropic hypogonadism in infants with congenital hypopituitarism: a challenge to diagnose at an early stage. Horm Res Paediatr. 2015;84(5):289–297.
   PubMed Web of Science ®Google Scholar
• Lambert AS, Bougnères P. Growth and descent of the testes in infants with hypogonadotropic hypogonadism receiving subcutaneous gonadotropin infusion. Int J Pediatr Endocrinol. 2016;13:2016.
   Google Scholar
• Vizeneux A, Hilfiger A, Bouligand J, et al. Congenital hypogonadotropic hypogonadism during childhood: presentation and genetic analyses in 46 boys. PLoS One. 2013;8(10):e77827.
   PubMed Web of Science ®Google Scholar
• Raivio T, Toppari J, Perheentupa A, et al. Treatment of prepubertal gonadotrophin-deficient boys with recombinant human follicle-stimulating hormone. Lancet. 1997;350(9073):263–264.
   PubMed Web of Science ®Google Scholar
• Main KM, Schmidt IM, Toppari J, et al. Early postnatal treatment of hypogonadotropic hypogonadism with recombinant human FSH and LH. Eur J Endocrinol. 2002;146(1):75–79.
   PubMed Web of Science ®Google Scholar
• Young J, Chanson P, Salenave S, et al. Testicular anti-mullerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2005;90(2):724–728.
   PubMed Web of Science ®Google Scholar
• Sykiotis GP, Hoang XH, Avbelj M, et al. Congenital idiopathic hypogonadotropic hypogonadism: evidence of defects in the hypothalamus, pituitary, and testes. J Clin Endocrinol Metab. 2010;95(6):3019–3027.
   PubMed Web of Science ®Google Scholar
• Dwyer AA, Sykiotis GP, Hayes FJ, et al. Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2013;98(11):E1790–1795.
   PubMed Web of Science ®Google Scholar
• Rohayem J, Hauffa BP, Zacharin M, et al. German adolescent hypogonadotropic hypogonadism study G. Testicular growth and spermatogenesis: new goals for pubertal hormone replacement in boys with hypogonadotropic hypogonadism? -a multicentre prospective study of hCG/rFSH treatment outcomes during adolescence. Clin Endocrinol (Oxf). 2017;86(1):75–87.
   PubMed Web of Science ®Google Scholar
• Stoupa A, Samara-Boustani D, Flechtner I, et al. Efficacy and safety of continuous subcutaneous infusion of recombinant human gonadotropins for congenital micropenis during early infancy. Horm Res Paediatr. 2017;87(2):103–110.
   PubMed Web of Science ®Google Scholar
• Rohayem J, Nieschlag E, Kliesch S, et al. Inhibin B, AMH, but not INSL3, IGF1 or DHEAS support differentiation between constitutional delay of growth and puberty and hypogonadotropic hypogonadism. Andrology. 2015;3(5):882–887.
   PubMed Web of Science ®Google Scholar
• Kohva E, Huopio H, Hero M, et al. Recombinant human FSH treatment outcomes in five boys with severe congenital hypogonadotropic hypogonadism. J Endocr Soc. 2018;2(12):1345–1356.
   PubMed Web of Science ®Google Scholar
• Edelsztein NY, Grinspon RP, Schteingart HF, et al. Anti-Müllerian hormone as a marker of steroid and gonadotropin action in the testis of children and adolescents with disorders of the gonadal axis. Int J Pediatr Endocrinol. 2016;20:2016.
   Google Scholar
• Chemes HE, Rey RA, Nistal M, et al. Physiological androgen insensitivity of the fetal, neonatal, and early infantile testis is explained by the ontogeny of the androgen receptor expression in Sertoli cells. J Clin Endocrinol Metab. 2008;93(11):4408–4412.
   PubMed Web of Science ®Google Scholar
• Rey RA, Belville C, Nihoul-Fékété C, et al. Evaluation of gonadal function in 107 intersex patients by means of serum antimüllerian hormone measurement. J Clin Endocrinol Metab. 1999;84(2):627–631.
   PubMed Web of Science ®Google Scholar
• Rey R, Josso N, Racine C. Sexual differentiation. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.;2000–2016 June 1. Available from: http://www.endotext.org/chapter/sexual-differentiation/.
   Google Scholar
• Lukas-Croisier C, Lasala C, Nicaud J, et al. Follicle-stimulating hormone increases testicular Anti-Müllerian hormone (AMH) production through sertoli cell proliferation and a nonclassical cyclic adenosine 5ʹ-monophosphate-mediated activation of the AMH gene. Mol Endocrinol. 2003;17(4):550–561.
   PubMedGoogle Scholar
• Dutertre M, Rey R, Porteu A, et al. A mouse Sertoli cell line expressing anti-Müllerian hormone and its type II receptor. Mol Cell Endocrinol. 1997;136(1):57–65.
   PubMed Web of Science ®Google Scholar
• Al-Attar L, Noël K, Dutertre M, et al. Hormonal and cellular regulation of Sertoli cell anti-Müllerian hormone production in the postnatal mouse. J Clin Invest. 1997;100(6):1335–1343.
   PubMed Web of Science ®Google Scholar
• Lasala C, Schteingart HF, Arouche N, et al. SOX9 and SF1 are involved in cyclic AMP-mediated upregulation of anti-Mullerian gene expression in the testicular prepubertal Sertoli cell line SMAT1. Am J Physiol Endocrinol Metab. 2011;301(3):E539–547.
   PubMed Web of Science ®Google Scholar
• Rey RA, Venara M, Coutant R, et al. Unexpected mosaicism of R201H-GNAS1 mutant-bearing cells in the testes underlie macro-orchidism without sexual precocity in McCune-Albright syndrome. Hum Mol Genet. 2006;15(24):3538–3543.
   PubMed Web of Science ®Google Scholar
• Hsueh AJ, Kawamura K, Cheng Y, et al. Intraovarian control of early folliculogenesis. Endocr Rev. 2015;36(1):1–24.
   PubMed Web of Science ®Google Scholar
• Dewailly D, Robin G, Peigne M, et al. Interactions between androgens, FSH, anti-Mullerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. Hum Reprod Update. 2016;22(6):709–724.
   PubMed Web of Science ®Google Scholar
• Taieb J, Grynberg M, Pierre A, et al. FSH and its second messenger cAMP stimulate the transcription of human anti-Mullerian hormone in cultured granulosa cells. Mol Endocrinol. 2011;25(4):645–655.
   PubMedGoogle Scholar
• Bry-Gauillard H, Larrat-Ledoux F, Levaillant JM, et al. Anti-Mullerian hormone and ovarian morphology in women with isolated hypogonadotropic hypogonadism/Kallmann syndrome. Effects of recombinant human FSH. J Clin Endocrinol Metab. 2017;102:1102–1111.
   PubMed Web of Science ®Google Scholar
• Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-Müllerian hormone. Reproduction. 2002;124(5):601–609.
   PubMed Web of Science ®Google Scholar
• Muttukrishna S, Yussoff H, Naidu M, et al. Serum anti-Mullerian hormone and inhibin B in disorders of spermatogenesis. Fertil.Steril. 2007;88(2):516–518.
   PubMed Web of Science ®Google Scholar
• Plotton I, Garby L, Morel Y, et al. Decrease of anti-Mullerian hormone in genetic spermatogenic failure. Andrologia. 2012;44(5):349–354.
   PubMed Web of Science ®Google Scholar
• Fénichel P, Rey R, Poggioli S, et al. Anti-Müllerian hormone as a seminal marker for spermatogenesis in non-obstructive azoospermia. Hum Reprod. 1999;14(8):2020–2024.
   PubMed Web of Science ®Google Scholar
• Rey RA, Grinspon RP, Gottlieb S, et al. Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach. Andrology. 2013;1(1):3–16.
   PubMed Web of Science ®Google Scholar
• Bastida MG, Rey RA, Bergadá I, et al. Establishment of testicular endocrine function impairment during childhood and puberty in boys with Klinefelter syndrome. Clin Endocrinol (Oxf). 2007;67(6):863–870.
   PubMed Web of Science ®Google Scholar
• Pacenza N, Pasqualini T, Gottlieb S, et al. Clinical Presentation of Klinefelter’s Syndrome: Differences According to Age. Int J Endocrinol. 2012;324835:2012.
   Google Scholar
• Cortes D, Clasen-Linde E, Hutson JM, et al. The Sertoli cell hormones inhibin-B and anti Mullerian hormone have different patterns of secretion in prepubertal cryptorchid boys. J Pediatr Surg. 2016;51(3):475–480.
   PubMed Web of Science ®Google Scholar
• Moniez S, Pienkowski C, Lepage B, et al. Noonan syndrome males display Sertoli cell-specific primary testicular insufficiency. Eur J Endocrinol. 2018;179(6):409–418.
   PubMed Web of Science ®Google Scholar
• Levi M, Hasky N, Stemmer SM, et al. Anti-Mullerian Hormone is a marker for chemotherapy-induced testicular toxicity. Endocrinology. 2015;156(10):3818–3827.
   PubMed Web of Science ®Google Scholar
• Jain M, Kalsi AK, Srivastava A, et al. High serum estradiol and heavy metals responsible for human spermiation defect-a pilot study. J Clin Diagn Res. 2016;10(12):RC09–RC13.
   PubMed Web of Science ®Google Scholar
• Goulis DG, Tsametis C, Iliadou PK, et al. Serum inhibin B and anti-Mullerian hormone are not superior to follicle-stimulating hormone as predictors of the presence of sperm in testicular fine-needle aspiration in men with azoospermia. Fertil Steril. 2009;91(4):1279–1284.
   PubMed Web of Science ®Google Scholar
• Toulis KA, Iliadou PK, Venetis CA, et al. Inhibin B and anti-Mullerian hormone as markers of persistent spermatogenesis in men with non-obstructive azoospermia: a meta-analysis of diagnostic accuracy studies. Hum Reprod Update. 2010;16(6):713–724.
   PubMed Web of Science ®Google Scholar
• Xu HY, Zhang HX, Xiao Z, et al. Regulation of anti-Mullerian hormone (AMH) in males and the associations of serum AMH with the disorders of male fertility. Asian J Androl. 2019;21(2):109-114.
   Web of Science ®Google Scholar
• Aksglaede L, Olesen IA, Carlsen E, et al. Serum concentration of anti-Mullerian hormone is not associated with semen quality. Andrology. 2018;6(2):286–292.
   PubMed Web of Science ®Google Scholar
• Raivio T, Wikström AM, Dunkel L. Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome. Eur J Endocrinol. 2007;156(1):105–111.
   PubMed Web of Science ®Google Scholar
• Young J, Rey R, Couzinet B, et al. Antimüllerian hormone in patients with hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 1999;84(8):2696–2699.
   PubMed Web of Science ®Google Scholar
• Sinisi AA, Esposito D, Maione L, et al. Seminal anti-Mullerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism. Hum.Reprod. 2008;23(5):1029–1034.
   PubMed Web of Science ®Google Scholar
• Caprio F, De Franciscis P, Trotta C, et al. Seminal anti-Mullerian hormone levels during recombinant human follicle-stimulating hormone treatment in men with idiopathic infertility undergoing assisted reproduction cycles. Andrology. 2015;3(5):843–847.
   PubMed Web of Science ®Google Scholar
• Guercio G, Rey RA. Fertility issues in the management of patients with disorders of sex development. Endocr Dev. 2014;27:87–98.
   PubMedGoogle Scholar
• Alfano M, Ventimiglia E, Locatelli I, et al. Anti-Mullerian Hormone-to-testosterone ratio is predictive of positive sperm retrieval in men with idiopathic non-obstructive azoospermia. Sci Rep. 2017;7(1):17638.
   PubMedGoogle Scholar
• Huhtaniemi I, Hovatta O, La Marca A, et al. Advances in the molecular pathophysiology, genetics, and treatment of primary ovarian insufficiency. Trends Endocrinol Metab. 2018;29(6):400-419.
   PubMed Web of Science ®Google Scholar
• Lew R. Natural history of ovarian function including assessment of ovarian reserve and premature ovarian failure. Best Pract Res Clin Obstet Gynaecol. 2019;55:2-13.
   PubMed Web of Science ®Google Scholar
• Sönmezer M, Özmen B, Atabekoglu CS, et al. Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism. J Assist Reprod Genet. 2012;29(7):597–602.
   PubMed Web of Science ®Google Scholar
• Chan C, Liu K. Clinical pregnancy in a woman with idiopathic hypogonadotropic hypogonadism and low AMH: utility of ovarian reserve markers in IHH. J Assist Reprod Genet. 2014;31(10):1317–1321.
   PubMed Web of Science ®Google Scholar
• Deubzer B, Weber K, Lawrenz B, et al. Anti-mullerian hormone deficiency in girls with congenital multiple pituitary hormone deficiency. J Clin Endocrinol Metab. 2014;99(6):E1045–1049.
   PubMed Web of Science ®Google Scholar
• Medicine PCotASfR. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106(7):1634–1647.
   PubMed Web of Science ®Google Scholar
• Catteau-Jonard S, Jamin SP, Leclerc A, et al. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(11):4456–4461.
   PubMed Web of Science ®Google Scholar
• Adan L, Lechevalier P, Couto-Silva AC, et al. Plasma inhibin B and antimullerian hormone concentrations in boys: Discriminating between congenital hypogonadotropic hypogonadism and constitutional pubertal delay. Med SciMonit. 2010;16(11):CR511–CR517.
   Web of Science ®Google Scholar
• Coutant R, Biette-Demeneix E, Bouvattier C, et al. Baseline inhibin B and anti-mullerian hormone measurements for diagnosis of hypogonadotropic hypogonadism (HH) in boys with delayed puberty. J Clin Endocrinol Metab. 2010;95(12):5225–5232.
   PubMed Web of Science ®Google Scholar
• Bougnères P, François M, Pantalone L, et al. Effects of an early postnatal treatment of hypogonadotropic hypogonadism with a continuous subcutaneous infusion of recombinant follicle-stimulating hormone and luteinizing hormone. J Clin Endocrinol Metab. 2008;93(6):2202–2205.
   PubMed Web of Science ®Google Scholar